Chronic conditions like heart failure (HF) and pulmonary arterial hypertension (PAH) have a severe negative impact on patients’ quality of life but are also among the largest sources of healthcare costs in the world.
Without optimal medication, HF and PAH patients cycle downward, experiencing multiple rehospitalizations where they fight for their lives and generate large medical costs.
HF readmissions are frequent and costly, averaging $25,000 per readmission, and over $15M in penalty costs per US HF center every year.
Without remote monitoring, <1% of HF patients are on optimal medication levels.1 This undermedication leads to decompensation and hospital readmissions.
Over half of PAH patients die before receiving the gold standard treatment, parenteral prostacyclins, due to a lack of remote oversight.2
Includes our proprietary medical-grade LTE-connected smartwatch, wireless weight scale, and blood sample collection kits. Companion mobile app is provided with personalized daily checklists, symptom checkers and messaging support with providers.
Powers effective remote management of HF patients by enabling clinicians to set custom alerts when any patient’s blood or digital biomarkers exceed a threshold. Clinicians may also perform deeper analyses of patients by reviewing their longitudinally collected biomarker data on any timescale.
Pre-configured, SIM-connected devices means that patients are quickly onboarded and uploading vital data to the cloud. Our warranty ensures that lost or broken items get replaced quickly with no fuss.
CardioID for PAH provides the same functionality as the HF platform but additionally offers clinicians remote access to patient condition with the Reveal 2.0 Lite Risk Score, without needing the patient to come to the clinic.
1. Greene, Stephen J., et al. “Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry.” Journal of the American College of Cardiology 72.4 (2018): 351-366.
2. Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry. J Hear Lung Transplant. 2013;32(11):1114-1122. doi:10.1016/j.healun.2013.08.010